Breast Cancer

Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication while reducing drug waste.

Courtney Moore, APRN, FNP-C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– disease.

The FDA has approved imlunestrant for the treatment of patients with ESR1-mutated ER+, HER2- metastatic breast cancer.

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median injection time of 2 minutes.

Courtney Moore, APRN, FNP-C, OCN, discusses how patient comorbidities and adverse effect profiles guide CDK4/6 inhibitor choice in the first-line setting.

Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors.

Familiarity with each component of antibody-drug conjugates helps nurses and APPs deliver proactive adverse event management to patients with cancer.

Catering supportive care to the individual being treated helps better meet the needs of each patient, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Experts share advice on tailoring frontline treatment and managing toxicities for individuals with hormone receptor–positive metastatic breast cancer.

Kelsey Martin, APRN, AG-ACNP-BC, AOCNP, discusses current ADCs in breast, bladder, and lung cancer and highlights promising agents in development.

Nurse practitioners give their advice on making treatment choices based on the patient’s medical history and preferences.

Paolo Tarantino, MD, PhD, discusses ADC structure, toxicity, and nursing consideration for the treatment of patients with breast cancer.

Melissa Rikal, MSN, FNP-BC, AOCNP, shares strategies to help nurses improve adherence and patient education for oral oncolytic therapies.

Melissa Rikal, MSN, FNP-BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

Oncology nurses play a key role in monitoring, managing, and personalizing CDK4/6 inhibitor treatment to minimize toxicities and protect quality of life, according to Courtney Moore, APRN, FNP-C, OCN.

A breast cancer survivorship expert shares her top advice for counseling patients on endocrine therapy at the 5-year mark.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, explains how educating patients about the Breast Cancer Index can support informed endocrine therapy decisions.

Treatment decisions for older adults after CDK4/6 inhibitors should be tailored, explained Courtney Moore, APRN, FNP-C, OCN.

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.

Kimberly Podsada, BSN, RN, MSN, NP-C, CNS, explained that understanding a patient’s emotional needs can help educate them on treatment adherence.

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in patients with breast cancer.

Survivorship expert Michelle Kirschner, MSN, RN, ACNP, APRN-BC, says that “doable changes” can enhance the lives of patients surviving cancer.

Adding aprepitant to chemotherapy was linked to longer survival in patients with non-luminal breast cancers, especially triple-negative breast cancer.

Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.